首页> 外文会议>Saratov Fall Meeting 2017: Optical Technologies in Biophysics and Medicine XIX >Evaluation of photodynamic treatment efficiency on glioblastoma cells received from malignant lesions - initial studies
【24h】

Evaluation of photodynamic treatment efficiency on glioblastoma cells received from malignant lesions - initial studies

机译:评估恶性病变中胶质母细胞瘤细胞的光动力治疗效率-初步研究

获取原文
获取原文并翻译 | 示例

摘要

Photodynamic therapy is well-established and extensively used method in treatment of different cancer types. This research reveals its potential in the treatment of cultivated human glioblastoma cells with adherent morphology. As the blood-brain barrier (BBB) permeability of the drugs is a significant problem that could not be solved easily for large biomolecules, we search for an appropriate low-molecular weight photosensitizer that could be applied for photodynamic treatment of glioblastoma cells. We used delta-aminolevulinic acid (5-ALA), which could pass BBB and plays the role of precursor of a protoporphyrin IX (PpIX) - photosensitizer, that is accumulated selectively in the tumour cells and could be a proper tool in PDT of glioblastoma. However, differences from patient to patient and between the cell activities could also lead to different effectiveness of the PDT treatment of the tumour areas. Therefore in our study we investigated not only the effect of using different fluence rates and light doses, but aims to establish more efficient values for further clinical applications for each sub-type of the GBM lesions. For the needs of PDT application an illumination device was developed in Laboratory of Biophotonics, BAS based on light-emitting diode (LED) matrix light sources for therapeutic application emitting at 635 nm. The device is optimized for PDT in combination with aminolevulinic acid/protoporphyrin IX applied as a photosensitizer drug. By the means of FACSCalibur flow cytometer (Becton Dickinson, USA) and Cell Quest Software was made evaluation of PDT effect on used human glioblastoma cells. Treatment of glioblastoma tumours continues to be a very serious issue and there is growing need in development of new concepts, methods and cancer-fighting strategies. PDT may contribute in accomplishing better results in cancer treatment and can be applied as well in combination with other techniques.
机译:光动力疗法是治疗不同癌症类型的公认且广泛使用的方法。这项研究揭示了其在培养具有粘附形态的人类胶质母细胞瘤细胞方面的潜力。由于药物的血脑屏障(BBB)渗透性是一个大生物分子不易解决的重要问题,因此我们寻求了一种适合用于胶质母细胞瘤细胞光动力治疗的低分子量光敏剂。我们使用了可以通过BBB并起原卟啉IX(PpIX)-光敏剂前体作用的δ-氨基乙酰丙酸(5-ALA),它在肿瘤细胞中选择性积累,并且可能是胶质母细胞瘤PDT的合适工具。然而,患者之间以及细胞活性之间的差异也可能导致PDT治疗肿瘤区域的有效性不同。因此,在我们的研究中,我们不仅研究了使用不同通量率和光剂量的效果,而且还旨在为GBM病变的每种亚型建立更有效的值,以用于进一步的临床应用。为了满足PDT应用的需要,BAS的Biophotonics实验室开发了一种照明装置,该装置基于发光二极管(LED)矩阵光源,用于635 nm发射的治疗应用。该设备已针对PDT与氨基乙酰丙酸/原卟啉IX组合用作光敏剂进行了优化。通过FACSCalibur流式细胞仪(Becton Dickinson,美国)和Cell Quest软件评估PDT对用过的人胶质母细胞瘤细胞的作用。胶质母细胞瘤肿瘤的治疗仍然是一个非常严重的问题,并且对开发新概念,新方法和抗癌策略的需求日益增长。 PDT可能有助于在癌症治疗中取得更好的结果,并且可以与其他技术结合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号